A Synthesis Method for Automatic Handling of Inter-patient Variability in Closed-loop Anesthesia

Soltesz, Kristian; van Heusden, Klaske; Hast, Martin; Ansermino, J. Mark; Dumont, Guy A.

Published in:
Proceedings of the 2016 American Control Conference

DOI:
10.1109/ACC.2016.7526125

2016

Document Version:
Peer reviewed version (aka post-print)

Link to publication

Citation for published version (APA):
A Synthesis Method for Automatic Handling of Inter-patient Variability in Closed-loop Anesthesia

Kristian Soltesz¹, Klaske van Heusden², Martin Hast¹, J. Mark Ansermino³, Guy A. Dumont²

Abstract—This paper presents a convex-optimization-based technique to obtain PID parameters, used to control the infusion rate of the anesthetic drug propofol. Controller design is based on a set of identified patient models, relating propofol infusion to an EEG-based consciousness index. The main contribution lies in the method automatically taking inter-patient variability into account, i.e., it guarantees robustness (sensitivity peak) and performance (disturbance rejection) over a set of patient models, without the need for manual intervention.

I. INTRODUCTION

This work considers closed-loop drug delivery in anesthesia. More specifically, propofol is dosed intravenously, to meet a desired consciousness level (also referred to as depth of hypnosis, DOH). The DOH is measured using the NeuroSense EEG monitor [1] and the hypnotic drug is administered by a computer-controller infusion pump. The control system is schematically depicted in Figure 1.

The main motivation for closed-loop controlled anesthesia is to reduce over-dosing, which could otherwise result in hemodynamic instability, and increases in both recovery time and post-operative mortality [2]. Clinical evaluation of several closed-loop systems has been reported [3], [4], [5], [6], [7], [8], [9]. These studies have shown the clinical feasibility of closed-loop anesthesia. However, for commercial products, it will be hard to demonstrate the safety of ad hoc control approaches. The main control challenge lies in robustly handling the large inter-patient variability in the response to propofol [10]. In a simulation study [11], a model predictive control approach was suggested, for which robustness was evaluated in presence of limited inter-patient variability.

The authors have developed a PID controller based system that was successfully evaluated in a clinical study comprising 102 children [12]. Currently, it is being evaluated on adults in a study of 150 cases [13], and a second pediatric study is scheduled. In order to design safe closed-loop controllers, dynamic models of the patients’ response to propofol are used, see Section II. As mentioned, such models hold large inter-patient variability, even after allometric regressions (such as scaling by patient weight). It is therefore critical that a closed-loop anesthesia delivery system be robust over the encountered inter-patient variability. For the study [12], this was achieved through robust loop shaping, evaluated over the set of available models [10], [14]. While providing robust controllers, the loop shaping was performed manually. Consequently, the controller design is suboptimal, and retuning of the controller is inefficient.

The novelty of this paper lies in the use of a recent convex-optimization-based synthesis method [15], removing the manual component from the synthesis procedure, while guaranteeing robustness up to a user-specified level. The method is demonstrated in two versions: one for producing a controller which performs robustly over a set of patient models, and one which performs robustly over an unstructured uncertainty description. The two versions of the synthesis method are demonstrated and compared, using models identified from clinical data [10]. A controller designed using the proposed method is scheduled for clinical evaluation.

II. PATIENT MODELS

A. PKPD Models

It is customary to model the patient’s response to propofol using a pharmacokinetic (PK) model, dynamically relating infusion rate \( u \) to plasma concentration \( C_p \), in series with a pharmacodynamic (PD) model, relating plasma concentration to clinical effect. The PK is traditionally modeled as a three-compartment mammillary model, i.e., a linear time invariant (LTI) system with three states. The PD model can be described by a first order time delay (FOTD) model, parametrized in \( k_{eo} \), relating the plasma concentration \( C_p \) to the effect site concentration \( C_e \), and a static sigmoid output nonlinearity, referred to as the Hill function. The latter can
be written on the form

\[ E(C_e) = \frac{E_0}{1 + (C_e/E_{C50})^{\gamma}}, \]  

(1)

where \( C_e \) is the output of the LTI model, \( E \) is the clinical effect, and \( E_0 \) the clinical effect in absence of drug. In this paper \( E \) is scaled such that \( 0 \leq E_0 < 1 \), while \( E = 1 \) corresponds to maximum clinical effect\(^b\). \( EC_{50} \) is the solution to \( E(EC_{50}) = (1 - E_0)/2 \), i.e., the 50 % clinical effect, and \( \gamma \) is known as the ”Hill parameter”. A block diagram of the combined PKPD model is shown in Figure 2a.

PKPD models (i.e., LTI state space matrices, together with \( E_0, EC_{50}, \gamma \)) for 47 children, identified from clinical data, were presented in [10] (together with corresponding low-order models, which could be used interchangeably, but would not be recognized by clinicians). Nyquist curves of the linearizations of these models (from \( u \) to \( E \) in Figure 2), around the (nominal clinical) operating point \( E = EC_{50} \) are shown as thin lines in Figure 3. These LTI models are referred to as the individual models, and, for each angular frequency \( \omega \), form the set \( P_\Omega = \{ P_{1}, \ldots, P_n \} \).c

The measurement of the clinical effect \( E \) is provided by means of the NeuroSense EEG monitor, which has LTI dynamics well approximated by \( M(s) = 1/(8s+1)^2 \) [16]. A low-pass filter, \( F(s) = 1/(15s+1)^2 \), is connected in series with the EEG monitor to reduce the effect of measurement noise. Without going into details, it should be mentioned that \( F \) must be chosen with the expected noise spectrum and open-loop high-frequency gain in consideration. Both \( M \) and \( F \) assume seconds as the unit of time. The relation between the clinical effect \( E \) and its measurement \( y_i \), available for control, is shown in Figure 2b.

\(^b\)An equivalent scaling where \( E = 0 \) and \( E = 100 \) corresponds to maximum and no clinical effect, respectively, is often found in the literature.

\(^c\)The argument \( i\omega \) will frequently be dropped to increase readability.
The nominal model $P_0$ and corresponding uncertainty discs $\Delta$, for each $\omega \in \Omega$, are shown in Figure 3, as a thick black line and a grey area, respectively.

III. CONTROLLER SYNTHESIS

A. Optimization Problems

The existing, clinically evaluated [12], control system utilizes a PID controller\(^d\) $C(s) = k_p + k_i/s + k_ds$, with fixed measurement filter according to Figure 2b. When performing the loop shaping, performance was assessed through time-domain simulations of disturbance attenuation over the set of models, while robustness was maintained by limiting the maximum sensitivity magnitude over the model set.

In this paper, the same control structure as above, is assumed. The optimization objective is maximization of the integral gain $k_i$. This corresponds to minimizing the integral of the error ($IE$), caused by a load step disturbance [18]. Robustness is enforced by constraining the maximum sensitivity magnitude over $\Omega$ by $M_s$. This formulation enables the use of the synthesis method proposed in [15].

Two cases will be considered: one where optimization is performed over the model set $P$, and one where it is performed over the uncertain model $\tilde{P}$. These cases will be referred to as the model set and uncertain-model approach.

1) Model Set Approach: Let $K = FMC$ denote the series connection of controller, low-pass filter and EEG monitor dynamics, see Figure 2b. Optimizing over the set of models, the constraints are given by

$$\|S\|_\infty = \|1/(1 + P_kK)\|_\infty \leq M_s, \forall P_k \in P.$$  

The optimization problem can be formalized as

$$\begin{align*}
\text{maximize} & \quad k_i, \\
\text{subject to} & \quad 1/M_s - |L_k + 1| \leq 0, \\
\text{and} & \quad L_k = P_kK,
\end{align*}$$  

where $L_k = P_kK$ is the open-loop transfer function. The problem (4) has $\#(\Omega)\#(P)$ inequality constraints, where $\#$ denotes element count.

2) Uncertain-Model Approach: In the uncertain-model approach, as formulated in [15], (3) is slightly modified: $S$ is exchanged for $\tilde{S} = 1/(1 + \tilde{P}K)$, eliminating the need to add individual constraints for each $P_k \in P$. The counterpart of (4) becomes

$$\begin{align*}
\text{maximize} & \quad k_i, \\
\text{subject to} & \quad 1/M_s + |K|\rho - |L_0 + 1| \leq 0,
\end{align*}$$  

where $L_0 = P_0K$ is the nominal open-loop transfer. The number of inequality constraints is $\#(\Omega)$. This is a decrease by a factor $\#(P)$, compared with the model set approach.

\(^d\)The ideal parallel form parametrization is used in favor of the more common standard form $C(s) = K(1 + 1/T_1s + T_2s)$, due to its linearity in the controller parameters.

B. The Convex-Concave Procedure

The constraints of both (4) and (5), correspond to circular disc in the Nyquist plane, which the open-loop transfer function(s) must avoid. In the model set approach, each open-loop Nyquist curve $L_k$ must maintain a distance $1/M_s$ to $-1$. In the uncertain-model approach, the nominal open-loop transfer function $L_0$ must maintain a distance $1/M_s + |K|\rho$ to $-1$, where the second term is in place to ensure robustness over $\tilde{P}$, rather than only $P_0$.

There is no efficient way to directly solve (4) or (5), as neither are convex programs (due to their constraints). A conservative approach, presented in [19], is to perform a convex relaxation. Each (non-convex) circle constraint is linearized, i.e., replaced by a half plane\(^e\). This corresponds to exchanging $|L + 1|$, where $L = L_k$ in (4) and $L = L_0$ in (5) for

$$\Re \left( \frac{(L + 1)^*}{|L + 1|} \right),$$  

where $\Re$ denotes the real part and $^*$ is the conjugate operator.

The convex relaxation honors constraints, since each circle is entirely contained in its corresponding half plane. However, the method is conservative for the same reason. This conservatism can be reduced by using the convex-concave procedure [20], which consists in iterating between performing the linearization (6) of (4) or (5) and solving the relaxed problem. (The solution of the last iteration is used to compute $L$ for the next iteration.) It was demonstrated in [15] that the class of PID synthesis problems considered in this paper can be efficiently solved using the convex-concave procedure.

The procedure can be initialized with the zero controller $[k_p, k_i, k_d] = [0 0 0]$, since it fulfills the constraints for any asymptotically stable plant.

While there are no guarantees of reaching the true optimum, the convex-concave procedure monotonically increases

\(^e\)Note that each $\omega \in \Omega$ generates an individual half plane, see Figure 5.
the objective in its iterations, while honoring constraints. This makes it safe (in terms of robustness constraints), while the added iteration step makes it perform at least as well (in terms of objective) as a controller resulting from [19].

IV. DESIGN CASE STUDY

A. Background

The aforementioned control system has undergone a clinical trial on 102 children in the age group 6–17 years [12]. The controller tuning was slightly modified during this trial, based on the 47 patient models $P_{all}$, reported in [10], to arrive at the final PID parameter vector $[k_p, k_i, k_d] = [1.1 0.0061 66]$, see [14]$^6$. The above numeric values assume negative feedback in continuous time, $u [\mu g/kg/min]$ (infused drug mass per patient weight per unit time), time scaled in seconds, and that $E$ is scaled as described in Section II-A. (The actual control system is sampled at 5 s, but we will utilize continuous time to facilitate readability.)

A second scheduled trial comprises children with an (inclusive) upper age limit of 10 years. For this trial, a controller tuning, based on the subset $P$ of the 47 available models, originating from children in the target age group, was requested. The new tuning was obtained using the proposed (automatic) method, in favor of (manual) loop shaping.

B. Controller Synthesis

Out of the 47 models in $P_{all}$, 20 were in the 6–10 (limits included) years age group. One outlier$^5$ was removed, and the set $P$ of the 19 remaining models was used for synthesis.

For the design example, we will ensure robustness by $M_s = 1.80$. For readers with a background in industrial control, this may seem like a large value. However, conservatism has been added at several stages along the design process:

- The patient models are inherently conservative, by purposeful over-estimation of their time delay [10].
- $M_s = 1.80$ corresponds to worst case (and not e.g. mean) robustness over the uncertain model $\hat{P}$.
- The uncertainty model $\Delta$ was conservatively chosen, see Section IV-B.2 and Figure 6.

For the same model set, the maximum sensitivity modulus obtained with the previously evaluated controller was $M_s = 1.84$.

In all examples to follow, solving convex programs was done using CVX$^b$. Execution times refer to ones obtained using a normal desktop computer.

$^6$In [14], controller parameters were reported in parallel form: $[K T, T_d] = [-6.6m/100 180 60]$, assuming plant gain scaled by a factor $-1/100 \cdot 60 \text{ min/h}/(10 \text{ mg/ml} \cdot m)$, where $m [\text{kg}]$ is the mass of the patient.

$^5$Model number 27 reported in [10] was removed. Occlusion of the propofol delivery line was registered during induction, and the resulting model had a very long estimated time delay.


1) Model Set Approach: The solution of (4) took 19.5 s and yielded the controller $K_1 = \text{FMC}_1$, where $C_1$ has parameter values $[k_p, k_i, k_d] = [1.4 0.0074 88]$. The corresponding open-loop Nyquist curves for $L_k = P_k K_1$ are shown as thin black lines in Figure 6. The distribution of $\|S\|_\infty$ over $P$ is shown (light grey) in Figure 7.

2) Uncertain-Model Approach: The uncertain model $\hat{P}$ was computed from $P$, by solving $|\Omega| = 1024$ instances of (5). Each instance had $|\Omega|$ = 19 inequality constraints. The computation to obtain $\hat{P}$ took 58 s. The actual design, i.e. solving the convex relaxation of (5) with $|\Omega| = 1024$ inequality constraints took 3.4 s.

The resulting controller $K_2 = \text{FMC}_2$ has $C_2$ parametrized by $[k_p, k_i, k_d] = [1.3 0.0056 73]$. The resulting nominal open-loop Nyquist curve $L_0 = P_0 K_2$ (thick black), its uncertain counterpart $\tilde{L} = P K_2$ (light grey), and the individual open loops $L_k = P_k K_2$ (dark grey) are shown in Figure 6.

As indicated by Figure 6, the uncertainty characterization introduces conservatism. While the design was carried out with the constraint $M_s = 1.80$, the resulting worst case over $P$ was $\|S\|_\infty = 1.68$ (with corresponding mean value $\|S\|_\infty = 1.34$). The distribution of $\|S\|_\infty$ over $P$ is shown (dark grey) in Figure 7.

A Bode plot comparison between the final tuning used in the [12], [14] (dashed black) and the new designs $K_1$ (solid black) and $K_2$ (grey), is shown in Figure 8.

C. Simulation Results

The resulting controllers were evaluated on the 19 individual nonlinear models (see Section IV-B). Figure 9 shows how the controllers transition the simulated patients from their
respective awake states $E = E_0$, to the setpoint $E = 0.5$. This transition is termed induction of anesthesia and the protocol (superimposed bolus) used for the simulations shown in Figure 9 is described in [12]. Black lines correspond to the model set design $K_1$, grey lines correspond to the uncertain model design $K_2$.

The maintenance phase begins upon induction of anesthesia. During this phase, it is the role of the controller to keep $E$ steady, in the presence of disturbances. The most notable disturbance is caused by surgical stimulation. It decreases $E$, and is typically modeled as as an additive output disturbance acting on the output of the PKPD model.

An output disturbance step of magnitude $\Delta E = -0.1$ was issued at $t = 0$ s, with simulations initiated at the equilibrium corresponding to $E = 0.5$. As is customary in many control contexts, we assume that the disturbance step response gives a fair assessment of the system’s disturbance attenuation ability.

The outcome of these simulations are shown in Figure 10, with line colors according to Figure 9. Although the control signals shown in Figure 9b and Figure 10b do not saturate, it is advisable to use an integrator anti-windup scheme in a clinical implementation, as was done in e.g. [14].

V. DISCUSSION

This paper proposes the use of the convex-concave procedure to obtain parameters for PID controllers, to be used in closed-loop controlled anesthesia. Feasibility has been demonstrated through a simulation case study, and a clinical trial of a controller obtained using the proposed method is currently scheduled.

The proposed method has several advantages over the manual loop shaping strategy used previously in [14]. It is entirely automatic, honors user-specified robustness constraints and maximizes an objective directly linked to disturbance attenuation performance.

Two versions of the synthesis method were proposed: the model set approach of Section IV-B.1, and the uncertain model approach of Section IV-B.2. Key differences between these approaches are briefly discussed below.

The uncertain model approach, with unstructured uncertainty computes by solving (2), adds conservatism, as can be seen by comparing the thin black lines and light grey area in Figure 6. The amount of conservatism added at a specific frequency is determined by the spread in frequency response of the design model set $P$, as illustrated in Figure 4. A related aspect, seen in Figure 3, is that model uncertainty is large for small $\omega$ (near the steady state), but small throughout the phase range critical for robust design. This is a direct consequence of the experimental conditions under which data for identification of $P$ was collected [10].
We have seen that the computation of controller parameters is fast (time scale of seconds), while it is more expensive (time scale of minutes) to compute the uncertain model \( \hat{P} \). It can, however, be noted that \( \hat{P} \) only needs to be computed once, upon which it can be used to solve several instances of the synthesis problem (to balance the trade-off between robustness and performance). Furthermore, the uncertain model approach results in constant time synthesis, regardless of the number of models used to generate the uncertain model \( \hat{P} \).

Which approach to choose depends on whether the extra conservatism introduced by the uncertain model \( \hat{P} \) is desired, in combination with the number of elements of \( \Omega \) and \( \hat{P} \). For the relatively small design example, with \( \#(P) = 19 \), presented in this paper, the time difference is not a critical design factor. However, scenarios where \( P \) consists of a large number of models, for which several designs are to be evaluated, would benefit from the uncertain model approach.

There is a close similarity between the controller presented in [14] and the herein proposed designs \( K_1 \) and \( K_2 \). This similarity is seen both in the frequency response shown Figure 8 and in the simulation outcomes shown in Figure 9 and Figure 10. It indicates that the controller used in [12] is close to optimal, in the sense considered in this paper. It also indicates that the methods proposed in this paper can be used to obtain clinically feasible controllers.

Finally, it can be noted that the constraint level \( M_s \) can be used to shift the trade-off between robustness and performance. That is, faster disturbance attenuation is possible, but it comes at the cost of decreased robustness to inter-patient variability.